Evidence map›Paper›PMID 39136024›Full record

ArticleFrontiers in immunology2024

Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens.

Tsima Abou Kors, Matthias Meier, Lena Mühlenbruch, Annika C Betzler, Franziska Oliveri, Martin Bens, Jaya Thomas, Johann M Kraus, Johannes Doescher, Adrian von Witzleben and 15 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tsima Abou KorsDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Matthias MeierDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Lena MühlenbruchDepartment of Immunology, Institute for Cell Biology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Annika C BetzlerDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Franziska OliveriDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Martin BensCore Facility Next Generation Sequencing, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany.
Jaya ThomasCancer Sciences Unit, University of Southampton, Faculty of Medicine, Southampton, United Kingdom.
Johann M KrausInstitute of Medical Systems Biology, Faculty of Medicine, Ulm University, Ulm, Germany.
Johannes DoescherDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Adrian von WitzlebenDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Linda HofmannDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Jasmin EzicDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Diana HuberDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Julian BenckendorffInstitute of Pathology, Ulm University Medical Center, Ulm, Germany.
Thomas F E BarthInstitute of Pathology, Ulm University Medical Center, Ulm, Germany.
Jens GreveDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Patrick J SchulerDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Cornelia BrunnerDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Jonathan M BlackburnInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Thomas K HoffmannDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Christian OttensmeierInstitute of Systems, Molecular and Integrative Biology, Liverpool Head and Neck Center, University of Liverpool, Faculty of Medicine, Liverpool, United Kingdom.
Hans A KestlerInstitute of Medical Systems Biology, Faculty of Medicine, Ulm University, Ulm, Germany.
Hans-Georg RammenseeDepartment of Immunology, Institute for Cell Biology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Juliane S WalzDepartment of Peptide-based Immunotherapy, Eberhard Karls University and University Hospital Tübingen, Tübingen, Germany.
Simon LabanDepartment of Otorhinolaryngology and Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The human leukocyte antigen complex (HLA) is essential for inducing specific immune responses to cancer by presenting tumor-associated peptides (TAP) to T cells. Overexpressed tumor associated antigens, mainly cancer-testis antigens (CTA), are outlined as essential targets for immunotherapy in oropharyngeal squamous cell carcinoma (OPSCC). This study assessed the degree to which presentation, gene expression, and antibody response (AR) of TAP, mainly CTA, are correlated in OPSCC patients to evaluate their potential as immunotherapy targets. Materials and methods: Snap-frozen tumor (N Results: 183 and 94 of HLA class I and II TAP were identified by comparative profiling with healthy tonsils. Genes from 26 TAP were overexpressed in tumors compared to healthy mucosa (LFC>1; FDR<0.05). Low concordance (r=0.25; p<0.0001) was found between upregulated mRNA and class I TAP. The specific mode of correlation of TAP was found to be dependent on clinical parameters. A lack of correlation was observed both between mRNA and class II TAP, as well as between class II tumor-unique TAP (TAP-U) presentation and antibody response (AR) levels. Discussion: This study demonstrates that focusing exclusively on gene transcript levels fails to capture the full extent of TAP presentation in OPSCC. Furthermore, our findings reveal that although CTA are presented at relatively low levels, a few CTA TAP-U show potential as targets for immunotherapy.

Indexed as

Antigens, NeoplasmOropharyngeal NeoplasmsAdultAgedAntibody FormationAntigen PresentationExome SequencingFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMultiomicsSquamous Cell Carcinoma of Head and NeckAntigens, Neoplasmantibody response (AR)cancer testis antigens (CTA)HLAoropharyngeal squamous cell carcinoma (OPSCC)tumor-associated peptide (TAP)

Identifiers

PMID39136024
PMCPMC11317303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.